Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters

被引:71
作者
Kung, Mei-Ping
Hou, Catherine
Goswami, Rajesh
Ponde, Datta E.
Kilbourn, Michael R.
Kung, Hank F. [1 ]
机构
[1] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA
[3] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA
关键词
9-fluoropropyl-dihydrotetrabenazine; vesicular monoamine transporters; PET imaging agent; POSITRON-EMISSION-TOMOGRAPHY; PARKINSONS-DISEASE; DOPAMINE TRANSPORTERS; RADIOLIGAND BINDING; BRAIN; DIHYDROTETRABENAZINE; RAT; TETRABENAZINE; METABOLITE; LIGAND;
D O I
10.1016/j.nucmedbio.2006.12.005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Labeling derivatives of dihydrotetrabenazine (DTBZ) with F-18 (T-1/(2) = 110 min) instead of C-11 (T-1/(2)=20 min) would improve their utility and availability for imaging vesicular monoamine transporters (VMAT2) in clinical settings. The successful synthesis, reported previously, of two novel 9-fluoroalkyl(+/-)-DTBZ ligands prompted us to study the optically resolved active ligand 9-fluoropropyl-(+)-DTBZ (FP-(+)DTBZ), which may have more promising characteristics. The inhibition constant (K-i) estimated for FP-(+)-DTBZ (using [3 H]()-DTBZ as the labeled ligand in rat striatal homogenates) showed a lower value as compared to the racemic FP-(+/-)-DTBZ (0.10 +/- 0.01 vs 0.19 +/- 0.04 nM). The inactive isomer, FP-(-)-DTBZ, displayed a much lower binding affinity with a K-i value > 3000 nM. Biodistribution studies in mice after an iv injection of [F-18]FP-(+)-DTBZ exhibited a ratio of striatum (ST, target) to cerebellum (CB, background) of 4.51 at 30 min postinjection, which is a higher value than previously obtained with the racemic ligand [F-18]FP-(+/-)-DTBZ (ST/CB=2.95). Brain extraction at 30 min after the tracer injection in mice showed that > 95% of the radioactivity corresponded to the parent, nonmetabolized, compound remaining in the ST, suggesting that the tracer has an excellent in vivo stability. Furthermore, localization of the tracer in the brain examined with ex vivo autoradiogaphy displayed a typical distribution pattern consistent with VMAT2 sites. The highest labeling was observed in monoaminergic neuron regions (caudate putamen, olfactory tubercle, nucleus accumbens, substantia nigra, dorsal raphe and locus coerules). We also tested the selective labeling of this tracer at the dopamine neurons in unilateral-lesioned inice (treated with 6-hydroxydopamine). When [F-18]FP-(+)-DTBZ and [I-125]IPT ((N-(3-iodopropen-2'-yl)-2-beta-carbomethoxy-3-beta-(4-chlorophenyl)tropane, a selective marker for dopamine transporters (DATs) in dopaminergic neurons) were simultaneously injected into lesioned mice, we observed an excellent correlation (r=0.95) for these tracers. From these findings, we conclude that [F-18]FP-(+)-DTBZ is a sensitive and selective tracer for VMAT2 binding sites and it may be useful for in vivo evaluation of diseases relating to changes of monoamine neuronal integrity. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:239 / 246
页数:8
相关论文
共 32 条
  • [1] Rapid loss of striatal VMAT2 binding associated with onset of Lewy body dementia
    Albin, R
    Koeppe, R
    [J]. MOVEMENT DISORDERS, 2006, 21 (02) : 287 - 288
  • [2] Increased ventral striatal monoaminergic innervation in Tourette syndrome
    Albin, RL
    Koeppe, RA
    Bohnen, NI
    Nichols, TE
    Meyer, P
    Wernette, K
    Minoshima, S
    Kilbourn, MR
    Frey, KA
    [J]. NEUROLOGY, 2003, 61 (03) : 310 - 315
  • [3] Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease
    Bohnen, Nicolaas I.
    Albin, Roger L.
    Koeppe, Robert A.
    Wernette, Kristine A.
    Kilbourn, Michael R.
    Minoshima, Satoshi
    Frey, Kirk A.
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2006, 26 (09) : 1198 - 1212
  • [4] Booij J, 1998, J NUCL MED, V39, P1879
  • [5] Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
    Frey, KA
    Koeppe, RA
    Kilbourn, MR
    VanderBorght, TM
    Albin, RL
    Gilman, S
    Kuhl, DE
    [J]. ANNALS OF NEUROLOGY, 1996, 40 (06) : 873 - 884
  • [6] Frey KA, 2001, ADV NEUROL, V86, P237
  • [7] Frey KA, 2002, EUR J NUCL MED MOL I, V29, P715, DOI 10.1007/s00259-002-0815-4
  • [8] Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters
    Goswami, Rajesh
    Ponde, Datta E.
    Kung, Mei-Ping
    Hou, Catherine
    Kilbourn, Mike R.
    Kung, Hank F.
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2006, 33 (06) : 685 - 694
  • [9] PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders
    Guilloteau, D
    Chalon, S
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (25) : 3237 - 3245
  • [10] SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHIC IMAGING DEMONSTRATES LOSS OF STRIATAL DOPAMINE TRANSPORTERS IN PARKINSON DISEASE
    INNIS, RB
    SEIBYL, JP
    SCANLEY, BE
    LARUELLE, M
    ABI-DARGHAM, A
    WALLACE, E
    BALDWIN, RM
    ZEAPONCE, Y
    ZOGHBI, S
    WANG, S
    GAO, Y
    NEUMEYER, JL
    CHARNEY, DS
    HOFFER, PB
    MAREK, KL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) : 11965 - 11969